PharmaEssentia (6446) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2025, rose 61% year-over-year to NTD 10,753.5 million, driven by strong medicine product sales and service revenue.

• Net income for the nine-month period increased 106% year-over-year to NTD 3,568.9 million, with EPS of NTD 9.66 (basic) and NTD 9.62 (diluted).

• The company operates as a single segment focused on medicine research and development.

Financial highlights

• Gross profit margin for the nine months was 89%, up from 88% year-over-year.

• Operating expenses increased 36% year-over-year, mainly due to higher R&D and administrative costs.

• Cash and cash equivalents stood at NTD 21,581.1 million as of September 30, 2025.

• Total assets reached NTD 34,450.0 million, up from NTD 29,144.6 million a year earlier.

• Total liabilities were NTD 4,700.8 million, with equity at NTD 29,749.2 million.

Outlook and guidance

• The company plans to expand into cell therapy by establishing a Shanghai subsidiary and acquiring ImmuXell Biotech Limited (Shanghai).

• Investment in Taiwan Bio-Manufacturing Corporation (TBMC) up to NTD 930 million to accelerate cell therapy and nucleic acid drug product lines.